BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R, Xu S, Zhang H, Cui G, Sun R, Wen H, Lerut JP, Kan Q, Li L, Zheng S. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68:1014-1023. [PMID: 30045880 DOI: 10.1136/gutjnl-2017-315084] [Cited by in Crossref: 156] [Cited by in F6Publishing: 154] [Article Influence: 39.0] [Reference Citation Analysis]
Number Citing Articles
1 Hartmann P. Editorial: The Microbiome in Hepatobiliary and Intestinal Disease. Front Physiol 2022;13:893074. [DOI: 10.3389/fphys.2022.893074] [Reference Citation Analysis]
2 Rao BC, Lou JM, Wang WJ, Li A, Cui GY, Yu ZJ, Ren ZG. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2020;19:109-15. [PMID: 32037278 DOI: 10.1016/j.hbpd.2020.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Ni X, Lin Z, Dai S, Chen H, Chen J, Zheng C, Wu B, Ao J, Shi K, Sun H. Screening and verification of microRNA promoter methylation sites in hepatocellular carcinoma. J Cell Biochem 2020;121:3626-41. [PMID: 32065423 DOI: 10.1002/jcb.29656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jian X, Zhu Y, Ouyang J, Wang Y, Lei Q, Xia J, Guan Y, Zhang J, Guo J, He Y, Wang J, Li J, Lin J, Su M, Li G, Wu M, Qiu L, Xiang J, Xie L, Jia W, Zhou W. Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria. Microbiome 2020;8:74. [PMID: 32466801 DOI: 10.1186/s40168-020-00854-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
5 Kang GU, Jung DR, Lee YH, Jeon SY, Han HS, Chong GO, Shin JH. Dynamics of Fecal Microbiota with and without Invasive Cervical Cancer and Its Application in Early Diagnosis. Cancers (Basel) 2020;12:E3800. [PMID: 33339445 DOI: 10.3390/cancers12123800] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Xu J, Zhan Q, Fan Y, Lo EKK, Zhang F, Yu Y, El-Nezami H, Zeng Z. Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management. Pathogens 2021;10:782. [PMID: 34206200 DOI: 10.3390/pathogens10070782] [Reference Citation Analysis]
7 Huang Z, Zeng S, Xiong J, Hou D, Zhou R, Xing C, Wei D, Deng X, Yu L, Wang H, Deng Z, Weng S, Kriengkrai S, Ning D, Zhou J, He J. Microecological Koch's postulates reveal that intestinal microbiota dysbiosis contributes to shrimp white feces syndrome. Microbiome 2020;8:32. [PMID: 32156316 DOI: 10.1186/s40168-020-00802-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 16.0] [Reference Citation Analysis]
8 Hou MF, Ou-Yang F, Li CL, Chen FM, Chuang CH, Kan JY, Wu CC, Shih SL, Shiau JP, Kao LC, Kao CN, Lee YC, Moi SH, Yeh YT, Cheng CJ, Chiang CP. Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer. Exp Mol Med 2021;53:1636-46. [PMID: 34707191 DOI: 10.1038/s12276-021-00686-9] [Reference Citation Analysis]
9 Ni J, Fu C, Huang R, Li Z, Li S, Cao P, Zhong K, Ge M, Gao Y. Metabolic syndrome cannot mask the changes of faecal microbiota compositions caused by primary hepatocellular carcinoma. Lett Appl Microbiol 2021;73:73-80. [PMID: 33768575 DOI: 10.1111/lam.13477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Qu D, Wang Y, Xia Q, Chang J, Jiang X, Zhang H. Intratumoral Microbiome of Human Primary Liver Cancer. Hepatol Commun 2022. [PMID: 35191218 DOI: 10.1002/hep4.1908] [Reference Citation Analysis]
11 Chen H, Zhang F, Zhang J, Zhang X, Guo Y, Yao Q. A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based on Microbiome-Metabolomics Analysis. Front Immunol 2020;11:588079. [PMID: 33072135 DOI: 10.3389/fimmu.2020.588079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Gao M, Wang H, Luo H, Sun Y, Wang L, Ding S, Ren H, Gang J, Rao B, Liu S, Wang X, Gao X, Li M, Zou Y, Liu C, Yuan C, Sun J, Cui G, Ren Z. Characterization of the Human Oropharyngeal Microbiomes in SARS-CoV-2 Infection and Recovery Patients. Adv Sci (Weinh) 2021;8:e2102785. [PMID: 34423593 DOI: 10.1002/advs.202102785] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Caussy C, Tripathi A, Humphrey G, Bassirian S, Singh S, Faulkner C, Bettencourt R, Rizo E, Richards L, Xu ZZ, Downes MR, Evans RM, Brenner DA, Sirlin CB, Knight R, Loomba R. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 2019;10:1406. [PMID: 30926798 DOI: 10.1038/s41467-019-09455-9] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 28.0] [Reference Citation Analysis]
14 Park SY, Hwang BO, Lim M, Ok SH, Lee SK, Chun KS, Park KK, Hu Y, Chung WY, Song NY. Oral-Gut Microbiome Axis in Gastrointestinal Disease and Cancer. Cancers (Basel) 2021;13:2124. [PMID: 33924899 DOI: 10.3390/cancers13092124] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Joishy TK, Jha A, Oudah M, Das S, Adak A, Deb D, Khan MR, Moreira TMM. Human Gut Microbes Associated with Systolic Blood Pressure. International Journal of Hypertension 2022;2022:1-12. [DOI: 10.1155/2022/2923941] [Reference Citation Analysis]
16 Manzoor SS, Doedens A, Burns MB. The promise and challenge of cancer microbiome research. Genome Biol 2020;21:131. [PMID: 32487228 DOI: 10.1186/s13059-020-02037-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
17 Sayed IM, Ramadan HK, El-mokhtar MA, Abdel-wahid L. Microbiome and gastrointestinal malignancies. Current Opinion in Physiology 2021;22:100451. [DOI: 10.1016/j.cophys.2021.06.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang S, Kong C, Yang Y, Cai S, Li X, Cai G, Ma Y. Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer. Theranostics 2020;10:11595-606. [PMID: 33052235 DOI: 10.7150/thno.49515] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
19 Yu B, Jin L, Chen Z, Nie W, Chen L, Ma Y, Chen H, Wu Y, Ma Y, Chen J, Han F. The gut microbiome in microscopic polyangiitis with kidney involvement: common and unique alterations, clinical association and values for disease diagnosis and outcome prediction. Ann Transl Med 2021;9:1286. [PMID: 34532423 DOI: 10.21037/atm-21-1315] [Reference Citation Analysis]
20 Blesl A, Jüngst C, Lammert F, Fauler G, Rainer F, Leber B, Feldbacher N, Stromberger S, Wildburger R, Spindelböck W, Fickert P, Horvath A, Stadlbauer V. Secondary Sclerosing Cholangitis in Critically Ill Patients Alters the Gut-Liver Axis: A Case Control Study. Nutrients 2020;12:E2728. [PMID: 32906634 DOI: 10.3390/nu12092728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ren Z, Chen X, Hong L, Zhao X, Cui G, Li A, Liu Y, Zhou L, Sun R, Shen S, Li J, Lou J, Zhou H, Wang J, Xu G, Yu Z, Song Y, Chen X. Nanoparticle Conjugation of Ginsenoside Rg3 Inhibits Hepatocellular Carcinoma Development and Metastasis. Small 2020;16:e1905233. [PMID: 31814271 DOI: 10.1002/smll.201905233] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
22 Reuter B, Bajaj JS. Microbiome: Emerging Concepts in Patients with Chronic Liver Disease.Clin Liver Dis. 2020;24:493-520. [PMID: 32620285 DOI: 10.1016/j.cld.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Chen YH, Xue F, Yu SF, Li XS, Liu L, Jia YY, Yan WJ, Tan QR, Wang HN, Peng ZW. Gut microbiota dysbiosis in depressed women: The association of symptom severity and microbiota function. J Affect Disord 2021;282:391-400. [PMID: 33421868 DOI: 10.1016/j.jad.2020.12.143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Long L, Liu X, Jin L, Simon T, Ma W, Kim MN, Yang W, Meyerhardt JA, Chan AT, Giovannucci E, Zhang X. Association of bowel movement frequency and laxative use with risk of hepatocellular carcinoma in US women and men. Int J Cancer 2021;149:1529-35. [PMID: 34028016 DOI: 10.1002/ijc.33699] [Reference Citation Analysis]
25 Hu X, Ouyang S, Xie Y, Gong Z, Du J. Characterizing the gut microbiota in patients with chronic kidney disease. Postgrad Med 2020;132:495-505. [PMID: 32241215 DOI: 10.1080/00325481.2020.1744335] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
26 Lu H, Yao Y, Yang J, Zhang H, Li L. Microbiome-miRNA interactions in the progress from undifferentiated arthritis to rheumatoid arthritis: evidence, hypotheses, and opportunities. Rheumatol Int 2021;41:1567-75. [PMID: 33856544 DOI: 10.1007/s00296-021-04798-3] [Reference Citation Analysis]
27 Scherz V, Greub G, Bertelli C. Building up a clinical microbiota profiling: a quality framework proposal. Crit Rev Microbiol 2021;:1-20. [PMID: 34752719 DOI: 10.1080/1040841X.2021.1975642] [Reference Citation Analysis]
28 Bringer MA, Gabrielle PH, Bron AM, Creuzot-Garcher C, Acar N. The gut microbiota in retinal diseases. Exp Eye Res 2021;214:108867. [PMID: 34856206 DOI: 10.1016/j.exer.2021.108867] [Reference Citation Analysis]
29 Yan S, Yin XM. Gut microbiome in liver pathophysiology and cholestatic liver disease. Liver Res 2021;5:151-63. [PMID: 35355516 DOI: 10.1016/j.livres.2021.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kaźmierczak-Siedlecka K, Skonieczna-Żydecka K, Hupp T, Duchnowska R, Marek-Trzonkowska N, Połom K. Next-generation probiotics - do they open new therapeutic strategies for cancer patients? Gut Microbes 2022;14:2035659. [PMID: 35167406 DOI: 10.1080/19490976.2022.2035659] [Reference Citation Analysis]
31 Jiang L, Stärkel P, Fan JG, Fouts DE, Bacher P, Schnabl B. The gut mycobiome: a novel player in chronic liver diseases. J Gastroenterol 2021;56:1-11. [PMID: 33151407 DOI: 10.1007/s00535-020-01740-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
32 Xu JY, Liu MT, Tao T, Zhu X, Fei FQ. The role of gut microbiota in tumorigenesis and treatment. Biomed Pharmacother 2021;138:111444. [PMID: 33662679 DOI: 10.1016/j.biopha.2021.111444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Hu S, Li A, Huang T, Lai J, Li J, Sublette ME, Lu H, Lu Q, Du Y, Hu Z, Ng CH, Zhang H, Lu J, Mou T, Lu S, Wang D, Duan J, Hu J, Huang M, Wei N, Zhou W, Ruan L, Li MD, Xu Y. Gut Microbiota Changes in Patients with Bipolar Depression. Adv Sci (Weinh) 2019;6:1900752. [PMID: 31380217 DOI: 10.1002/advs.201900752] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
34 Shen R, Ke L, Li Q, Dang X, Shen S, Shen J, Li S, Liang L, Peng B, Kuang M, Ma Y, Yang Z, Hua Y. Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma. Hepatol Int 2022. [PMID: 35211843 DOI: 10.1007/s12072-022-10299-7] [Reference Citation Analysis]
35 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
36 Yamamoto K, Honda T, Ito T, Ishizu Y, Kuzuya T, Nakamura M, Miyahara R, Kawashima H, Ishigami M, Fujishiro M. The relationship between oral-origin bacteria in the fecal microbiome and albumin-bilirubin grade in patients with hepatitis C. J Gastroenterol Hepatol 2021;36:790-9. [PMID: 32744764 DOI: 10.1111/jgh.15206] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Zhang N, Gou Y, Liang S, Chen N, Liu Y, He Q, Zhang J. Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response. J Immunol Res 2021;2021:4973589. [PMID: 34722779 DOI: 10.1155/2021/4973589] [Reference Citation Analysis]
38 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
39 Lou J, Jiang Y, Rao B, Li A, Ding S, Yan H, Zhou H, Liu Z, Shi Q, Cui G, Yu Z, Ren Z. Fecal Microbiomes Distinguish Patients With Autoimmune Hepatitis From Healthy Individuals. Front Cell Infect Microbiol 2020;10:342. [PMID: 32850468 DOI: 10.3389/fcimb.2020.00342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Cai K, Ma Y, Cai F, Huang X, Xiao L, Zhong C, Ren P, Luo Q, Chen J, Han F. Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury. Endocrine 2022. [PMID: 35246764 DOI: 10.1007/s12020-022-03002-1] [Reference Citation Analysis]
41 Altay O, Nielsen J, Uhlen M, Boren J, Mardinoglu A. Systems biology perspective for studying the gut microbiota in human physiology and liver diseases. EBioMedicine 2019;49:364-73. [PMID: 31636011 DOI: 10.1016/j.ebiom.2019.09.057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
42 Wu L, Feng J, Li J, Yu Q, Ji J, Wu J, Dai W, Guo C. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed Pharmacother 2021;133:111036. [PMID: 33378947 DOI: 10.1016/j.biopha.2020.111036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Dong R, Bai M, Zhao J, Wang D, Ning X, Sun S. A Comparative Study of the Gut Microbiota Associated With Immunoglobulin a Nephropathy and Membranous Nephropathy. Front Cell Infect Microbiol 2020;10:557368. [PMID: 33194798 DOI: 10.3389/fcimb.2020.557368] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
44 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
45 Yu Q, Wu L, Ji J, Feng J, Dai W, Li J, Wu J, Guo C. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:271-88. [PMID: 33150145 DOI: 10.2147/JHC.S277870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Ho CM, Chen HL, Hu RH, Lee PH. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective. Ther Adv Med Oncol 2019;11:1758835919843463. [PMID: 31065295 DOI: 10.1177/1758835919843463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
47 Liang G. Altered gut bacterial and metabolic signatures and their interaction in inflammatory bowel disease. Synth Syst Biotechnol 2021;6:377-83. [PMID: 34820530 DOI: 10.1016/j.synbio.2021.10.003] [Reference Citation Analysis]
48 Lin Z, Ni X, Dai S, Chen H, Chen J, Wu B, Ao J, Shi K, Sun H. Screening and verification of long noncoding RNA promoter methylation sites in hepatocellular carcinoma. Cancer Cell Int 2020;20:311. [PMID: 32684848 DOI: 10.1186/s12935-020-01407-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease. FEBS J 2019;287:833-55. [DOI: 10.1111/febs.15217] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 22.5] [Reference Citation Analysis]
50 Jia J, Tian X, Jiang J, Ren Z, Lu H, He N, Xie H, Zhou L, Zheng S. Structural shifts in the intestinal microbiota of rats treated with cyclosporine A after orthotropic liver transplantation. Front Med 2019;13:451-60. [PMID: 31020543 DOI: 10.1007/s11684-018-0675-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
51 Cho EJ, Leem S, Kim SA, Yang J, Lee YB, Kim SS, Cheong JY, Cho SW, Kim JW, Kim SM, Yoon JH, Park T. Circulating Microbiota-Based Metagenomic Signature for Detection of Hepatocellular Carcinoma. Sci Rep 2019;9:7536. [PMID: 31101866 DOI: 10.1038/s41598-019-44012-w] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
52 Deng Y, Tang D, Hou P, Shen W, Li H, Wang T, Liu R. Dysbiosis of gut microbiota in patients with esophageal cancer. Microb Pathog 2021;150:104709. [PMID: 33378710 DOI: 10.1016/j.micpath.2020.104709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
53 He C, Wang H, Yu C, Peng C, Shu X, Liao W, Zhu Z. Alterations of Gut Microbiota in Patients With Intestinal Tuberculosis That Different From Crohn's Disease. Front Bioeng Biotechnol 2021;9:673691. [PMID: 34295880 DOI: 10.3389/fbioe.2021.673691] [Reference Citation Analysis]
54 Wei Z, Ren Z, Hu S, Gao Y, Sun R, Lv S, Yang G, Yu Z, Kan Q. Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease. Cancer Med 2020;9:1254-62. [PMID: 31860170 DOI: 10.1002/cam4.2777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
55 Yu W, Shang J, Guo R, Zhang F, Zhang W, Zhang Y, Wu F, Ren H, Liu C, Xiao J, Zhao Z. The gut microbiome in differential diagnosis of diabetic kidney disease and membranous nephropathy. Ren Fail 2020;42:1100-10. [PMID: 33121301 DOI: 10.1080/0886022X.2020.1837869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
56 Zhang Z, Tang H, Chen P, Xie H, Tao Y. Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. Signal Transduct Target Ther 2019;4:41. [PMID: 31637019 DOI: 10.1038/s41392-019-0074-5] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
57 Su X, Zhao Y, Li Y, Ma S, Wang Z. Gut dysbiosis is associated with primary hypothyroidism with interaction on gut-thyroid axis. Clin Sci (Lond) 2020;134:1521-35. [PMID: 32519746 DOI: 10.1042/CS20200475] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
58 Zeng S, Khoruamkid S, Kongpakdee W, Wei D, Yu L, Wang H, Deng Z, Weng S, Huang Z, He J, Satapornvanit K. Dissimilarity of microbial diversity of pond water, shrimp intestine and sediment in Aquamimicry system. AMB Express 2020;10:180. [PMID: 33025112 DOI: 10.1186/s13568-020-01119-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
59 Xu X, Feng X, He M, Zhang Z, Wang J, Zhu H, Li T, Wang F, Sun M, Wang Z. The effect of acupuncture on tumor growth and gut microbiota in mice inoculated with osteosarcoma cells. Chin Med 2020;15:33. [PMID: 32292489 DOI: 10.1186/s13020-020-00315-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
60 Yang Y, Du L, Shi D, Kong C, Liu J, Liu G, Li X, Ma Y. Dysbiosis of human gut microbiome in young-onset colorectal cancer. Nat Commun 2021;12:6757. [PMID: 34799562 DOI: 10.1038/s41467-021-27112-y] [Reference Citation Analysis]
61 Jiang H, Zhao X, Zang M, Fu R, Shao Z, Liu C, Gambini J. Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome. Oxidative Medicine and Cellular Longevity 2022;2022:1-21. [DOI: 10.1155/2022/1482811] [Reference Citation Analysis]
62 Nishimura N, Kaji K, Kitagawa K, Sawada Y, Furukawa M, Ozutsumi T, Fujinaga Y, Tsuji Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Fukui H, Yoshiji H. Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. Int J Mol Sci 2021;22:6921. [PMID: 34203178 DOI: 10.3390/ijms22136921] [Reference Citation Analysis]
63 Wei ZL, Zhou X, Lan CL, Huang HS, Liao XW, Mo ST, Wei YG, Peng T. Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma. BMC Gastroenterol 2022;22:77. [PMID: 35193513 DOI: 10.1186/s12876-022-02152-w] [Reference Citation Analysis]
64 Rattan P, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. Liver Transpl. 2020;26:1316-1327. [PMID: 32564483 DOI: 10.1002/lt.25828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
65 Abdelsalam NA, Ramadan AT, ElRakaiby MT, Aziz RK. Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics. Front Pharmacol 2020;11:390. [PMID: 32372951 DOI: 10.3389/fphar.2020.00390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
66 Wang Y, Pan CQ, Xing H. Advances in Gut Microbiota of Viral Hepatitis Cirrhosis. Biomed Res Int 2019;2019:9726786. [PMID: 31886272 DOI: 10.1155/2019/9726786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
67 Zeng S, Zhou R, Bao S, Li X, Deng Z, Hou D, Weng S, He J, Huang Z. Identification of Multigene Biomarker for Shrimp White Feces Syndrome by Full-Length Transcriptome Sequencing. Front Genet 2020;11:71. [PMID: 32133029 DOI: 10.3389/fgene.2020.00071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
68 Wu R, Mei X, Ye Y, Xue T, Wang J, Sun W, Lin C, Xue R, Zhang J, Xu D. Zn(II)-curcumin solid dispersion impairs hepatocellular carcinoma growth and enhances chemotherapy by modulating gut microbiota-mediated zinc homeostasis. Pharmacol Res 2019;150:104454. [PMID: 31526871 DOI: 10.1016/j.phrs.2019.104454] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
69 Rao B, Ren T, Wang X, Wang H, Zou Y, Sun Y, Liu S, Ren Z, Yu Z. Dysbiosis in the Human Microbiome of Cholangiocarcinoma. Front Physiol 2021;12:715536. [PMID: 34867436 DOI: 10.3389/fphys.2021.715536] [Reference Citation Analysis]
70 Grochowska M, Perlejewski K, Laskus T, Radkowski M. The Role of Gut Microbiota in Gastrointestinal Tract Cancers. Arch Immunol Ther Exp (Warsz) 2022;70:7. [PMID: 35112169 DOI: 10.1007/s00005-021-00641-6] [Reference Citation Analysis]
71 Dong Y, Lu J, Wang T, Huang Z, Chen X, Ren Z, Hong L, Wang H, Yang D, Xie H, Zhang W. Multi-Omics Analysis Reveals Disturbance of Nanosecond Pulsed Electric Field in the Serum Metabolic Spectrum and Gut Microbiota. Front Microbiol 2021;12:649091. [PMID: 34276585 DOI: 10.3389/fmicb.2021.649091] [Reference Citation Analysis]
72 Sehgal R, Bedi O, Trehanpati N. Role of Microbiota in Pathogenesis and Management of Viral Hepatitis.Front Cell Infect Microbiol. 2020;10:341. [PMID: 32850467 DOI: 10.3389/fcimb.2020.00341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
73 Gedgaudas R, Bajaj JS, Skieceviciene J, Varkalaite G, Jurkeviciute G, Gelman S, Valantiene I, Zykus R, Pranculis A, Bang C, Franke A, Schramm C, Kupcinskas J. Circulating microbiome in patients with portal hypertension. Gut Microbes 2022;14:2029674. [PMID: 35130114 DOI: 10.1080/19490976.2022.2029674] [Reference Citation Analysis]
74 Aishanjiang K, Wei XD, Fu Y, Lin X, Ma Y, Le J, Han Q, Wang X, Kong X, Gu J, Wu H. Circular RNAs and Hepatocellular Carcinoma: New Epigenetic Players With Diagnostic and Prognostic Roles. Front Oncol 2021;11:653717. [PMID: 33959506 DOI: 10.3389/fonc.2021.653717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Ren Z, Fan Y, Li A, Shen Q, Wu J, Ren L, Lu H, Ding S, Ren H, Liu C, Liu W, Gao D, Wu Z, Guo S, Wu G, Liu Z, Yu Z, Li L. Alterations of the Human Gut Microbiome in Chronic Kidney Disease. Adv Sci (Weinh) 2020;7:2001936. [PMID: 33101877 DOI: 10.1002/advs.202001936] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
76 D'Amico F, Perrone AM, Rampelli S, Coluccelli S, Barone M, Ravegnini G, Fabbrini M, Brigidi P, De Iaco P, Turroni S. Gut Microbiota Dynamics during Chemotherapy in Epithelial Ovarian Cancer Patients Are Related to Therapeutic Outcome. Cancers (Basel) 2021;13:3999. [PMID: 34439153 DOI: 10.3390/cancers13163999] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Liu X, Chen Y, Zhang S, Dong L. Gut microbiota-mediated immunomodulation in tumor. J Exp Clin Cancer Res 2021;40:221. [PMID: 34217349 DOI: 10.1186/s13046-021-01983-x] [Reference Citation Analysis]
78 Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. Int J Mol Sci 2021;22:7800. [PMID: 34360566 DOI: 10.3390/ijms22157800] [Reference Citation Analysis]
79 Ni J, Huang R, Zhou H, Xu X, Li Y, Cao P, Zhong K, Ge M, Chen X, Hou B, Yu M, Peng B, Li Q, Zhang P, Gao Y. Analysis of the Relationship Between the Degree of Dysbiosis in Gut Microbiota and Prognosis at Different Stages of Primary Hepatocellular Carcinoma. Front Microbiol 2019;10:1458. [PMID: 31293562 DOI: 10.3389/fmicb.2019.01458] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
80 Liu B, Lin W, Chen S, Xiang T, Yang Y, Yin Y, Xu G, Liu Z, Liu L, Pan J, Xie L. Gut Microbiota as an Objective Measurement for Auxiliary Diagnosis of Insomnia Disorder. Front Microbiol 2019;10:1770. [PMID: 31456757 DOI: 10.3389/fmicb.2019.01770] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
81 Hao Z, Tao K, Wu K, Luo Y, Lu Y, Li B, Shi P, Wang P, Zeng X, Lin Y. Alterations of gut microbiome and metabolite profiles in choledocholithiasis concurrent with cholangitis. Hepatol Int 2021. [PMID: 34313944 DOI: 10.1007/s12072-021-10231-5] [Reference Citation Analysis]
82 Marizzoni M, Gurry T, Provasi S, Greub G, Lopizzo N, Ribaldi F, Festari C, Mazzelli M, Mombelli E, Salvatore M, Mirabelli P, Franzese M, Soricelli A, Frisoni GB, Cattaneo A. Comparison of Bioinformatics Pipelines and Operating Systems for the Analyses of 16S rRNA Gene Amplicon Sequences in Human Fecal Samples. Front Microbiol 2020;11:1262. [PMID: 32636817 DOI: 10.3389/fmicb.2020.01262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
83 Cheng C, Wang Z, Wang J, Ding C, Sun C, Liu P, Xu X, Liu Y, Chen B, Gu B. Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer. Transl Lung Cancer Res 2020;9:693-704. [PMID: 32676331 DOI: 10.21037/tlcr-19-590] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
84 Bi C, Xiao G, Liu C, Yan J, Chen J, Si W, Zhang J, Liu Z. Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer. Front Cell Dev Biol 2021;9:702414. [PMID: 34957088 DOI: 10.3389/fcell.2021.702414] [Reference Citation Analysis]
85 Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L. Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol 2019; 25(30): 4199-4212 [PMID: 31435173 DOI: 10.3748/wjg.v25.i30.4199] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
86 Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. Front Med (Lausanne) 2020;7:361. [PMID: 32850884 DOI: 10.3389/fmed.2020.00361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
87 Qu L, Ma X, Fan D. Ginsenoside Rk3 Suppresses Hepatocellular Carcinoma Development through Targeting the Gut-Liver Axis. J Agric Food Chem 2021;69:10121-37. [PMID: 34415764 DOI: 10.1021/acs.jafc.1c03279] [Reference Citation Analysis]
88 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
89 Zhou A, Tang L, Zeng S, Lei Y, Yang S, Tang B. Gut microbiota: A new piece in understanding hepatocarcinogenesis. Cancer Lett 2020;474:15-22. [PMID: 31917160 DOI: 10.1016/j.canlet.2020.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
90 Huang H, Ren Z, Gao X, Hu X, Zhou Y, Jiang J, Lu H, Yin S, Ji J, Zhou L, Zheng S. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. Genome Med. 2020;12:102. [PMID: 33225985 DOI: 10.1186/s13073-020-00796-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
91 Pan Y, Chen H, Yu J. Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines 2020;8:E576. [PMID: 33297335 DOI: 10.3390/biomedicines8120576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, J G T Vehreschild M, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Mohr R, Lammert F, Tacke F, Schnabl B, Goeser T, Steffen HM, Demir M. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. Liver Int 2021;41:1576-91. [PMID: 33896117 DOI: 10.1111/liv.14899] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Ilan Y. Why targeting the microbiome is not so successful: can randomness overcome the adaptation that occurs following gut manipulation? Clin Exp Gastroenterol 2019;12:209-17. [PMID: 31190948 DOI: 10.2147/CEG.S203823] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
94 Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries. Front Immunol 2021;12:622064. [PMID: 33708214 DOI: 10.3389/fimmu.2021.622064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
95 Li J, Lu H, Wu H, Huang S, Chen L, Gui Q, Zhou W, Yang Y, Wu Y, Zhang H, Zhang Q, Yang Y. Periodontitis in elderly patients with type 2 diabetes mellitus: impact on gut microbiota and systemic inflammation. Aging (Albany NY) 2020;12:25956-80. [PMID: 33234730 DOI: 10.18632/aging.202174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
96 Van Hul M, Le Roy T, Prifti E, Dao MC, Paquot A, Zucker JD, Delzenne NM, Muccioli G, Clément K, Cani PD. From correlation to causality: the case of Subdoligranulum. Gut Microbes 2020;12:1-13. [PMID: 33323004 DOI: 10.1080/19490976.2020.1849998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
97 Jiang J, Mei J, Yi S, Feng C, Ma Y, Liu Y, Liu Y, Chen C. Tumor associated macrophage and microbe: The potential targets of tumor vaccine delivery. Adv Drug Deliv Rev 2021;180:114046. [PMID: 34767863 DOI: 10.1016/j.addr.2021.114046] [Reference Citation Analysis]
98 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
99 Gupta H, Youn GS, Shin MJ, Suk KT. Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms. 2019;7:pii: E121. [PMID: 31060311 DOI: 10.3390/microorganisms7050121] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
100 Wang X, Liu H, Li Y, Huang S, Zhang L, Cao C, Baker PN, Tong C, Zheng P, Qi H. Altered gut bacterial and metabolic signatures and their interaction in gestational diabetes mellitus. Gut Microbes 2020;12:1-13. [PMID: 33222612 DOI: 10.1080/19490976.2020.1840765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
101 Xiang X, Wang R, Chen L, Chen Y, Zheng B, Deng S, Liu S, Sun P, Shen G. Immunomodulatory activity of a water-soluble polysaccharide extracted from mussel on cyclophosphamide-induced immunosuppressive mice models. NPJ Sci Food 2022;6:26. [PMID: 35478196 DOI: 10.1038/s41538-022-00140-8] [Reference Citation Analysis]
102 Paratore M, Santopaolo F, Cammarota G, Pompili M, Gasbarrini A, Ponziani FR. Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. J Clin Med 2021;10:2605. [PMID: 34204748 DOI: 10.3390/jcm10122605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, Fragomeli V, Koay YC, Jackson M, O'Sullivan J, Weltman M, McCaughan G, El-Omar E, Zekry A. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021;12:187. [PMID: 33420074 DOI: 10.1038/s41467-020-20422-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
104 Zamora-León SP. Hepatocellular carcinoma biomarkers, an imminent need. World J Gastrointest Oncol 2021; 13(11): 1847-1849 [PMID: 34853655 DOI: 10.4251/wjgo.v13.i11.1847] [Reference Citation Analysis]
105 Liu B, Zhou Z, Jin Y, Lu J, Feng D, Peng R, Sun H, Mu X, Li C, Chen Y. Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma. J Immunother Cancer 2022;10:e003069. [PMID: 34996812 DOI: 10.1136/jitc-2021-003069] [Reference Citation Analysis]
106 Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Adv Cancer Res 2021;149:171-255. [PMID: 33579424 DOI: 10.1016/bs.acr.2020.10.004] [Reference Citation Analysis]
107 Chen L, Zhang L, Wang W, Qiu W, Liu L, Ning A, Cao J, Huang M, Zhong M. Polysaccharides isolated from Cordyceps Sinensis contribute to the progression of NASH by modifying the gut microbiota in mice fed a high-fat diet. PLoS One 2020;15:e0232972. [PMID: 32512581 DOI: 10.1371/journal.pone.0232972] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
108 Giraud J, Saleh M. Host-Microbiota Interactions in Liver Inflammation and Cancer. Cancers (Basel) 2021;13:4342. [PMID: 34503151 DOI: 10.3390/cancers13174342] [Reference Citation Analysis]
109 Zhang C, Liu S, Yang M. Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. Front Endocrinol (Lausanne) 2021;12:808526. [PMID: 35002979 DOI: 10.3389/fendo.2021.808526] [Reference Citation Analysis]
110 Hamada T, Nowak JA, Milner DA jr. Song M, Ogino S. Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. J Pathol. 2019;247:615-628. [PMID: 30632609 DOI: 10.1002/path.5236] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 16.0] [Reference Citation Analysis]
111 Li H, Liu F, Lu J, Shi J, Guan J, Yan F, Li B, Huo G. Probiotic Mixture of Lactobacillus plantarum Strains Improves Lipid Metabolism and Gut Microbiota Structure in High Fat Diet-Fed Mice.Front Microbiol. 2020;11:512. [PMID: 32273874 DOI: 10.3389/fmicb.2020.00512] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
112 Shan DD, Zheng QX, Wang J, Chen Z. Small nucleolar RNA host gene 3 functions as a novel biomarker in liver cancer and other tumour progression. World J Gastroenterol 2022; 28(16): 1641-1655 [DOI: 10.3748/wjg.v28.i16.1641] [Reference Citation Analysis]
113 Wang T, Huang S, Wu C, Wang N, Zhang R, Wang M, Mao D. Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine. Evid Based Complement Alternat Med 2021;2021:6682581. [PMID: 33976705 DOI: 10.1155/2021/6682581] [Reference Citation Analysis]
114 Deng T, Li J, He B, Chen B, Liu F, Chen Z, Zheng J, Shi Z, Zhang T, Deng L, Yu H, Yang J, Wu L, Shan Y, Yu Z, Chen X, Wang Y, Chen G. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer. Hepatol Int. [DOI: 10.1007/s12072-021-10279-3] [Reference Citation Analysis]
115 Singh D, Khan MA, Siddique HR. Therapeutic implications of probiotics in microbiota dysbiosis: A special reference to the liver and oral cancers. Life Sci 2021;285:120008. [PMID: 34606851 DOI: 10.1016/j.lfs.2021.120008] [Reference Citation Analysis]
116 Nischalke HD, Fischer J, Klüners A, Matz-Soja M, Krämer B, Langhans B, Goeser F, Soyka M, Stickel F, Spengler U, Nattermann J, Strassburg CP, Berg T, Lutz P. A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. Liver Int 2021;41:2139-48. [PMID: 34051061 DOI: 10.1111/liv.14980] [Reference Citation Analysis]
117 Ryu G, Kim H, Koh A. Approaching precision medicine by tailoring the microbiota. Mamm Genome 2021;32:206-22. [PMID: 33646347 DOI: 10.1007/s00335-021-09859-3] [Reference Citation Analysis]
118 Li H, Liu B, Song J, An Z, Zeng X, Li J, Jiang J, Xie L, Wu W. Characteristics of Gut Microbiota in Patients with Hypertension and/or Hyperlipidemia: A Cross-Sectional Study on Rural Residents in Xinxiang County, Henan Province. Microorganisms 2019;7:E399. [PMID: 31561625 DOI: 10.3390/microorganisms7100399] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
119 Schwabe RF, Greten TF. Gut microbiome in HCC - Mechanisms, diagnosis and therapy. J Hepatol. 2020;72:230-238. [PMID: 31954488 DOI: 10.1016/j.jhep.2019.08.016] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 51.0] [Reference Citation Analysis]
120 Newsome RC, Yang Y, Jobin C. The microbiome, gastrointestinal cancer, and immunotherapy. J Gastroenterol Hepatol 2021. [PMID: 34820895 DOI: 10.1111/jgh.15742] [Reference Citation Analysis]
121 Jaye K, Li CG, Bhuyan DJ. The complex interplay of gut microbiota with the five most common cancer types: From carcinogenesis to therapeutics to prognoses. Crit Rev Oncol Hematol 2021;165:103429. [PMID: 34293459 DOI: 10.1016/j.critrevonc.2021.103429] [Reference Citation Analysis]
122 Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol 2021;18:167-80. [PMID: 33257833 DOI: 10.1038/s41575-020-00376-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
123 Wu LL, Huang TS, Shyu YC, Wang CL, Wang HY, Chen PJ. Gut microbiota in the innate immunity against hepatitis B virus - implication in age-dependent HBV clearance. Curr Opin Virol 2021;49:194-202. [PMID: 34242953 DOI: 10.1016/j.coviro.2021.06.006] [Reference Citation Analysis]
124 Eom JA, Kwon GH, Kim NY, Park EJ, Won SM, Jeong JJ, Raja G, Gupta H, Asmelash Gebru Y, Sharma S, Choi YR, Kim HS, Yoon SJ, Hyun JY, Jeong MK, Park HJ, Min BH, Choi MR, Kim DJ, Suk KT. Diet-Regulating Microbiota and Host Immune System in Liver Disease. Int J Mol Sci 2021;22:6326. [PMID: 34199182 DOI: 10.3390/ijms22126326] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Bagheri Z, Moeinzadeh L, Razmkhah M. Roles of Microbiota in Cancer: From Tumor Development to Treatment. J Oncol 2022;2022:3845104. [PMID: 35342407 DOI: 10.1155/2022/3845104] [Reference Citation Analysis]
126 Nicoletti A, Pompili M, Gasbarrini A, Ponziani FR. Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8:295-7. [PMID: 31245418 DOI: 10.21037/hbsn.2019.01.16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Cammarota G, Ianiro G, Ahern A, Carbone C, Temko A, Claesson MJ, Gasbarrini A, Tortora G. Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nat Rev Gastroenterol Hepatol 2020;17:635-48. [DOI: 10.1038/s41575-020-0327-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
128 Federici S, Suez J, Elinav E. Our Microbiome: On the Challenges, Promises, and Hype. In: Kloc M, editor. Symbiosis: Cellular, Molecular, Medical and Evolutionary Aspects. Cham: Springer International Publishing; 2020. pp. 539-57. [DOI: 10.1007/978-3-030-51849-3_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Ngowi EE, Wang YZ, Khattak S, Khan NH, Mahmoud SSM, Helmy YASH, Jiang QY, Li T, Duan SF, Ji XY, Wu DD. Impact of the factors shaping gut microbiota on obesity. J Appl Microbiol 2021. [PMID: 33570819 DOI: 10.1111/jam.15036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Hussain SK, Dong TS, Agopian V, Pisegna JR, Durazo FA, Enayati P, Sundaram V, Benhammou JN, Noureddin M, Choi G, Ayoub WS, Lagishetty V, Elashoff D, Goodman MT, Jacobs JP. Dietary Protein, Fiber and Coffee Are Associated with Small Intestine Microbiome Composition and Diversity in Patients with Liver Cirrhosis. Nutrients 2020;12:E1395. [PMID: 32414035 DOI: 10.3390/nu12051395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
131 Albhaisi S, Shamsaddini A, Fagan A, McGeorge S, Sikaroodi M, Gavis E, Patel S, Davis BC, Acharya C, Sterling RK, Matherly S, Fuchs M, Gillevet PM, Bajaj JS. Gut Microbial Signature of Hepatocellular Cancer in Men With Cirrhosis. Liver Transpl 2021;27:629-40. [PMID: 33492761 DOI: 10.1002/lt.25994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
132 Turjeman S, Koren O. Using the microbiome in clinical practice. Microb Biotechnol 2022;15:129-34. [PMID: 34767683 DOI: 10.1111/1751-7915.13971] [Reference Citation Analysis]
133 Vaziri F, Colquhoun S, Wan YY. Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. Liver Res 2020;4:191-8. [PMID: 33343967 DOI: 10.1016/j.livres.2020.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
134 Lapidot Y, Amir A, Nosenko R, Uzan-Yulzari A, Veitsman E, Cohen-Ezra O, Davidov Y, Weiss P, Bradichevski T, Segev S, Koren O, Safran M, Ben-Ari Z. Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma. mSystems. 2020;5. [PMID: 32546668 DOI: 10.1128/msystems.00153-20] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
135 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
136 Zheng Y, Fang Z, Xue Y, Zhang J, Zhu J, Gao R, Yao S, Ye Y, Wang S, Lin C, Chen S, Huang H, Hu L, Jiang GN, Qin H, Zhang P, Chen J, Ji H. Specific gut microbiome signature predicts the early-stage lung cancer. Gut Microbes 2020;11:1030-42. [PMID: 32240032 DOI: 10.1080/19490976.2020.1737487] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
137 Zheng YY, Wu TT, Liu ZQ, Li A, Guo QQ, Ma YY, Zhang ZL, Xun YL, Zhang JC, Wang WR, Kadir P, Wang DY, Ma YT, Zhang JY, Xie X. Gut Microbiome-Based Diagnostic Model to Predict Coronary Artery Disease. J Agric Food Chem 2020;68:3548-57. [PMID: 32100534 DOI: 10.1021/acs.jafc.0c00225] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
138 Ma T, Ru J, Xue J, Schulz S, Mirzaei MK, Janssen KP, Quante M, Deng L. Differences in Gut Virome Related to Barrett Esophagus and Esophageal Adenocarcinoma. Microorganisms 2021;9:1701. [PMID: 34442780 DOI: 10.3390/microorganisms9081701] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Kang GU, Ibal JC, Lee S, Jang MH, Park YJ, Kim MC, Park TH, Kim MS, Kim RH, Shin JH. Alteration of the Soil Microbiota in Ginseng Rusty Roots: Application of Machine Learning Algorithm to Explore Potential Biomarkers for Diagnostic and Predictive Analytics. J Agric Food Chem 2021;69:8298-306. [PMID: 34043355 DOI: 10.1021/acs.jafc.1c01314] [Reference Citation Analysis]
140 Luo Y, Teng F, Fu H, Ding GS. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World J Gastrointest Oncol 2022; 14(1): 163-180 [DOI: 10.4251/wjgo.v14.i1.163] [Reference Citation Analysis]
141 Lu HF, Ren ZG, Li A, Zhang H, Xu SY, Jiang JW, Zhou L, Ling Q, Wang BH, Cui GY, Chen XH, Zheng SS, Li LJ. Fecal Microbiome Data Distinguish Liver Recipients With Normal and Abnormal Liver Function From Healthy Controls. Front Microbiol 2019;10:1518. [PMID: 31333622 DOI: 10.3389/fmicb.2019.01518] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
142 Sędzikowska A, Szablewski L. Human Gut Microbiota in Health and Selected Cancers. Int J Mol Sci 2021;22:13440. [PMID: 34948234 DOI: 10.3390/ijms222413440] [Reference Citation Analysis]
143 Zhou Y, Hu L, Tang W, Li D, Ma L, Liu H, Zhang S, Zhang X, Dong L, Shen X, Chen S, Xue R, Zhang S. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism. J Hematol Oncol 2021;14:9. [PMID: 33413510 DOI: 10.1186/s13045-020-01028-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Yang H, Jin X, Cheng T, Shan G, Lu C, Gu J, Zhan C, Xu F, Ge D. Comprehensive Genome-Scale Analysis of Esophageal Carcinoma With Esophageal Tissue-Resident Micro-Environment Discrepancy. Front Microbiol 2022;13:859352. [DOI: 10.3389/fmicb.2022.859352] [Reference Citation Analysis]
145 Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W, Yin W, Fang W. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer 2022;10:e003133. [PMID: 35101942 DOI: 10.1136/jitc-2021-003133] [Reference Citation Analysis]
146 Liu YX, Qin Y, Chen T, Lu M, Qian X, Guo X, Bai Y. A practical guide to amplicon and metagenomic analysis of microbiome data. Protein Cell 2021;12:315-30. [PMID: 32394199 DOI: 10.1007/s13238-020-00724-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
147 Wang Q, Su B, Dong L, Jiang T, Tan Y, Lu X, Liu X, Lin X, Xu G. Liquid Chromatography-Mass Spectrometry-Based Nontargeted Metabolomics Predicts Prognosis of Hepatocellular Carcinoma after Curative Resection. J Proteome Res. 2020;19:3533-3541. [PMID: 32618195 DOI: 10.1021/acs.jproteome.0c00344] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
148 Mima K, Kosumi K, Baba Y, Hamada T, Baba H, Ogino S. The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction. Hum Genet 2021;140:725-46. [PMID: 33180176 DOI: 10.1007/s00439-020-02235-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
149 Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Liu J, Krawczyk M, Nowag A, Kretzschmar A, Herweg J, Schnabl B, Tu XM, Lammert F, Goeser T, Tacke F, Heinzer K, Kasper P, Steffen HM, Demir M. High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. Hepatol Commun 2020;4:681-95. [PMID: 32363319 DOI: 10.1002/hep4.1509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
150 Bian Y, Chen X, Cao H, Xie D, Zhu M, Yuan N, Lu L, Lu B, Wu C, Bahaji Azami NL, Wang Z, Wang H, Zhang Y, Li K, Ye G, Sun M. A correlational study of Weifuchun and its clinical effect on intestinal flora in precancerous lesions of gastric cancer. Chin Med 2021;16:120. [PMID: 34801051 DOI: 10.1186/s13020-021-00529-9] [Reference Citation Analysis]
151 Rao B, Lou J, Lu H, Liang H, Li J, Zhou H, Fan Y, Zhang H, Sun Y, Zou Y, Wu Z, Jiang Y, Ren Z, Yu Z. Oral Microbiome Characteristics in Patients With Autoimmune Hepatitis. Front Cell Infect Microbiol 2021;11:656674. [PMID: 34094998 DOI: 10.3389/fcimb.2021.656674] [Reference Citation Analysis]
152 Jiang S, Lu S, Chen X, Li F, Zhu C, Zheng Y, Wang X, Xu S. Dysbiosis of urine microbiota in obstructive urinary retention patients revealed by next-generation sequencing. Ann Clin Microbiol Antimicrob 2021;20:2. [PMID: 33407528 DOI: 10.1186/s12941-020-00408-5] [Reference Citation Analysis]
153 Veziant J, Villéger R, Barnich N, Bonnet M. Gut Microbiota as Potential Biomarker and/or Therapeutic Target to Improve the Management of Cancer: Focus on Colibactin-Producing Escherichia coli in Colorectal Cancer. Cancers (Basel) 2021;13:2215. [PMID: 34063108 DOI: 10.3390/cancers13092215] [Reference Citation Analysis]
154 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
155 Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World J Gastrointest Oncol 2021; 13(11): 1616-1631 [PMID: 34853639 DOI: 10.4251/wjgo.v13.i11.1616] [Reference Citation Analysis]
156 Milosevic I, Russo E, Vujovic A, Barac A, Stevanovic O, Gitto S, Amedei A. Microbiota and viral hepatitis: State of the art of a complex matter. World J Gastroenterol 2021; 27(33): 5488-5501 [PMID: 34588747 DOI: 10.3748/wjg.v27.i33.5488] [Reference Citation Analysis]
157 Said I, Ahad H, Said A. Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics. World J Gastrointest Oncol 2022; 14(5): 947-958 [DOI: 10.4251/wjgo.v14.i5.947] [Reference Citation Analysis]
158 Zhang Y, Shen J, Shi X, Du Y, Niu Y, Jin G, Wang Z, Lyu J. Gut microbiome analysis as a predictive marker for the gastric cancer patients. Appl Microbiol Biotechnol 2021;105:803-14. [PMID: 33404833 DOI: 10.1007/s00253-020-11043-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
159 Dong Z, Chen B, Pan H, Wang D, Liu M, Yang Y, Zou M, Yang J, Xiao K, Zhao R, Zheng X, Zhang L, Zhang Y. Detection of Microbial 16S rRNA Gene in the Serum of Patients With Gastric Cancer. Front Oncol 2019;9:608. [PMID: 31338330 DOI: 10.3389/fonc.2019.00608] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
160 Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919848184. [PMID: 31205505 DOI: 10.1177/1758835919848184] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
161 Baker SS, Baker RD. Gut Microbiota and Liver Injury (II): Chronic Liver Injury. Adv Exp Med Biol 2020;1238:39-54. [PMID: 32323179 DOI: 10.1007/978-981-15-2385-4_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
162 Sun X, Pan CQ, Xing H. Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection. Hepatol Int 2021;15:1053-67. [PMID: 34596865 DOI: 10.1007/s12072-021-10230-6] [Reference Citation Analysis]
163 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
164 Queck A, Carnevale R, Uschner FE, Schierwagen R, Klein S, Jansen C, Meyer C, Praktiknjo M, Thomas D, Strassburg C, Zeuzem S, Violi F, Trebicka J. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut 2020;69:1535-6. [PMID: 31270166 DOI: 10.1136/gutjnl-2019-319044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
165 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
166 Xiao Q, Lu W, Kong X, Shao YW, Hu Y, Wang A, Bao H, Cao R, Liu K, Wang X, Wu X, Zheng S, Yuan Y, Ding K. Alterations of circulating bacterial DNA in colorectal cancer and adenoma: A proof-of-concept study. Cancer Lett 2021;499:201-8. [PMID: 33249197 DOI: 10.1016/j.canlet.2020.11.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
167 Zhang T, Zhang S, Jin C, Lin Z, Deng T, Xie X, Deng L, Li X, Ma J, Ding X, Liu Y, Shan Y, Yu Z, Wang Y, Chen G, Li J. A Predictive Model Based on the Gut Microbiota Improves the Diagnostic Effect in Patients With Cholangiocarcinoma. Front Cell Infect Microbiol 2021;11:751795. [PMID: 34888258 DOI: 10.3389/fcimb.2021.751795] [Reference Citation Analysis]
168 Ren Z, Wang H, Cui G, Lu H, Wang L, Luo H, Chen X, Ren H, Sun R, Liu W, Liu X, Liu C, Li A, Wang X, Rao B, Yuan C, Zhang H, Sun J, Chen X, Li B, Hu C, Wu Z, Yu Z, Kan Q, Li L. Alterations in the human oral and gut microbiomes and lipidomics in COVID-19. Gut 2021;70:1253-65. [PMID: 33789966 DOI: 10.1136/gutjnl-2020-323826] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
169 Ai D, Xing Y, Zhang Q, Wang Y, Liu X, Liu G, Xia LC. Joint Analysis of Microbial and Immune Cell Abundance in Liver Cancer Tissue Using a Gene Expression Profile Deconvolution Algorithm Combined With Foreign Read Remapping. Front Immunol 2022;13:853213. [DOI: 10.3389/fimmu.2022.853213] [Reference Citation Analysis]
170 Wang C, Li Q, Tang C, Zhao X, He Q, Tang X, Ren J. Characterization of the blood and neutrophil-specific microbiomes and exploration of potential bacterial biomarkers for sepsis in surgical patients. Immun Inflamm Dis 2021. [PMID: 34288545 DOI: 10.1002/iid3.483] [Reference Citation Analysis]
171 Chen Z, Xie Y, Zhou F, Zhang B, Wu J, Yang L, Xu S, Stedtfeld R, Chen Q, Liu J, Zhang X, Xu H, Ren J. Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease. Front Microbiol 2020;11:383. [PMID: 32265857 DOI: 10.3389/fmicb.2020.00383] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
172 Zeng J, Zhang G, Chen C, Li K, Wen Y, Zhao J, Wu P. Alterations in Urobiome in Patients With Bladder Cancer and Implications for Clinical Outcome: A Single-Institution Study. Front Cell Infect Microbiol 2020;10:555508. [PMID: 33384966 DOI: 10.3389/fcimb.2020.555508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
173 Adolph TE, Effenberger M, Tilg H. How our understanding of the microbiome has changed the way we look at liver diseases. Biomark Med 2018;12:1203-6. [PMID: 30444134 DOI: 10.2217/bmm-2018-0266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Anand S, Bose C, Kaur H, Mande SS. 'GutFeel': an in silico method for predicting gut health status based on the metabolic functional capabilities of the resident microbiome. FEBS Lett 2021;595:1825-43. [PMID: 33997973 DOI: 10.1002/1873-3468.14107] [Reference Citation Analysis]
175 Zheng R, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. Cancer Med 2020;9:4232-50. [PMID: 32281295 DOI: 10.1002/cam4.3045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
176 Jiang JW, Chen XH, Ren Z, Zheng SS. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis. Hepatobiliary Pancreat Dis Int 2019;18:19-27. [PMID: 30527903 DOI: 10.1016/j.hbpd.2018.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
177 Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, Zhang Y, Liu X. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathog. 2019;11:1. [PMID: 30675188 DOI: 10.1186/s13099-018-0281-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
178 Zhao Q, Wongpoomchai R, Chariyakornkul A, Xiao Z, Pilapong C. Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics. Front Oncol 2021;11:740484. [PMID: 34745960 DOI: 10.3389/fonc.2021.740484] [Reference Citation Analysis]
179 Kumar V, Xin X, Ma J, Tan C, Osna N, Mahato RI. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv Rev 2021;:113888. [PMID: 34314787 DOI: 10.1016/j.addr.2021.113888] [Reference Citation Analysis]
180 Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Front Oncol 2021;11:617335. [PMID: 33777757 DOI: 10.3389/fonc.2021.617335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
181 Russo E, Fiorindi C, Giudici F, Amedei A. Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma. World J Hepatol 2022; 14(2): 372-385 [DOI: 10.4254/wjh.v14.i2.372] [Reference Citation Analysis]
182 Liu B, Pan X, Liu Z, Han M, Xu G, Dai X, Wang W, Zhang H, Xie L. Fecal microbiota as a noninvasive biomarker to predict the tissue iron accumulation in intestine epithelial cells and liver. FASEB J 2020;34:3006-20. [PMID: 31912587 DOI: 10.1096/fj.201901635RR] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
183 Sun Q, Xu X, Zhang J, Sun M, Tian Q, Li Q, Cao W, Zhang X, Wang H, Liu J, Zhang J, Meng X, Wu L, Song M, Liu H, Wang W, Wang Y. Association of suboptimal health status with intestinal microbiota in Chinese youths. J Cell Mol Med 2020;24:1837-47. [PMID: 31808612 DOI: 10.1111/jcmm.14880] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
184 Yang XA, Lv F, Wang R, Chang Y, Zhao Y, Cui X, Li H, Yang S, Li S, Zhao X, Mo Z, Yang F. Potential role of intestinal microflora in disease progression among patients with different stages of Hepatitis B.Gut Pathog. 2020;12:50. [PMID: 33117435 DOI: 10.1186/s13099-020-00391-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
185 Lai J, Li A, Jiang J, Yuan X, Zhang P, Xi C, Wu L, Wang Z, Chen J, Lu J, Lu S, Mou T, Zhou H, Wang D, Huang M, Dong F, Li MD, Xu Y, Song X, Hu S. Metagenomic analysis reveals gut bacterial signatures for diagnosis and treatment outcome prediction in bipolar depression. Psychiatry Res 2022;307:114326. [PMID: 34896845 DOI: 10.1016/j.psychres.2021.114326] [Reference Citation Analysis]
186 Lu S, Yang Y, Xu Q, Wang S, Yu J, Zhang B, Wang Z, Zhang Y, Lu W, Hong K. Gut Microbiota and Targeted Biomarkers Analysis in Patients With Cognitive Impairment. Front Neurol 2022;13:834403. [DOI: 10.3389/fneur.2022.834403] [Reference Citation Analysis]
187 Lin YJ, Ho CM. Is the Rationale of Anatomical Liver Resection for Hepatocellular Carcinoma Universally Adoptable? A Hypothesis-Driven Review. Medicina (Kaunas) 2021;57:131. [PMID: 33540784 DOI: 10.3390/medicina57020131] [Reference Citation Analysis]
188 Silveira MAD, Bilodeau S, Greten TF, Wang XW, Trinchieri G. The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis. Trends Cancer 2022:S2405-8033(22)00045-0. [PMID: 35331674 DOI: 10.1016/j.trecan.2022.02.009] [Reference Citation Analysis]
189 Zeng Y, Chen S, Fu Y, Wu W, Chen T, Chen J, Yang B, Ou Q. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J Viral Hepat 2020;27:143-55. [PMID: 31600845 DOI: 10.1111/jvh.13216] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
190 Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res 2020;50:817-30. [PMID: 32323426 DOI: 10.1111/hepr.13506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
191 Shehab-Eldeen S, Metwaly MF, Saber SM, El-Kousy SM, Badr EA, Essa A. MicroRNA-29a and MicroRNA-124 as novel biomarkers for hepatocellular Carcinoma. Dig Liver Dis 2022:S1590-8658(22)00259-6. [PMID: 35525722 DOI: 10.1016/j.dld.2022.04.015] [Reference Citation Analysis]
192 Méndez-Sánchez N, Valencia-Rodriguez A, Vera-Barajas A, Abenavoli L, Scarpellini E, Ponciano-Rodriguez G, Wang DQ. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. Hepatoma Res 2020;6:5. [PMID: 32582865 DOI: 10.20517/2394-5079.2019.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
193 Wang L, Lin N, Lin K, Xiao C, Wang R, Chen J, Zhou W, Liu J. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study. J Gastrointest Surg 2021;25:1172-83. [PMID: 32440804 DOI: 10.1007/s11605-020-04588-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
194 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines 2021;9:1524. [PMID: 34829753 DOI: 10.3390/biomedicines9111524] [Reference Citation Analysis]
195 Almeida JI, Tenreiro MF, Martinez-Santamaria L, Aspizua SG, Gisbert JP, Alves PM, Serra M, Baptista PM. Hallmarks of the human intestinal microbiome on liver maturation and function. J Hepatol 2021:S0168-8278(21)02152-8. [PMID: 34715263 DOI: 10.1016/j.jhep.2021.10.015] [Reference Citation Analysis]
196 Mohieldeen K, Hamoda SAF, Ahmed SM, Najeeb A, Ellakany WI. Gut microbiome in cirrhotic hepatitis C virus patients with and without hepatocellular carcinoma. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00147-y] [Reference Citation Analysis]
197 Wu Y, Jiao N, Zhu R, Zhang Y, Wu D, Wang AJ, Fang S, Tao L, Li Y, Cheng S, He X, Lan P, Tian C, Liu NN, Zhu L. Identification of microbial markers across populations in early detection of colorectal cancer. Nat Commun 2021;12:3063. [PMID: 34031391 DOI: 10.1038/s41467-021-23265-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Wu YN, Zhang L, Chen T, Li X, He LH, Liu GX. Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation. World J Gastroenterol 2020; 26(36): 5420-5436 [PMID: 33024394 DOI: 10.3748/wjg.v26.i36.5420] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Guan MC, Ouyang W, Wang MD, Liang L, Li N, Fu TT, Shen F, Lau WY, Xu QR, Huang DS, Zhu H, Yang T. Biomarkers for hepatocellular carcinoma based on body fluids and feces. World J Gastrointest Oncol 2021; 13(5): 351-365 [PMID: 34040698 DOI: 10.4251/wjgo.v13.i5.351] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
200 Li Z, Chen G, Wang P, Sun M, Zhao J, Li A, Sun Q. Alterations of the Oral Microbiota Profiles in Chinese Patient With Oral Cancer. Front Cell Infect Microbiol 2021;11:780067. [PMID: 34956932 DOI: 10.3389/fcimb.2021.780067] [Reference Citation Analysis]
201 Hong G, Li Y, Yang M, Li G, Qian W, Xiong H, Bai T, Song J, Zhang L, Hou X. Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: An explorative study. Neurogastroenterol Motil 2020;32:e13891. [PMID: 32449259 DOI: 10.1111/nmo.13891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]